Leukocyte immunoglobulin-like receptor

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (09:40, 10 July 2024) (edit) (undo)
 
Line 6: Line 6:
*'''LILRA5''' has a role in triggering innate immune responses.
*'''LILRA5''' has a role in triggering innate immune responses.
*'''LILRB1''' interacts with classical and non-classical human leukocyte antigen (HLA) class I molecules<ref>PMID:37781391</ref>.
*'''LILRB1''' interacts with classical and non-classical human leukocyte antigen (HLA) class I molecules<ref>PMID:37781391</ref>.
-
*'''LILRB3'''I s a target for treatment against acute myeloid leukaemia<ref>PMID:38098451</ref>.
+
*'''LILRB3''' is a target for treatment against acute myeloid leukaemia<ref>PMID:38098451</ref>.
*'''LILRB4''' suppresses immunity in solid tumors<ref>PMID:33974041</ref>.
*'''LILRB4''' suppresses immunity in solid tumors<ref>PMID:33974041</ref>.

Current revision

Structure of human leukocyte immunoglobulin-like receptor ligand-binding domain (salmon) complex with class I MHC (aqua), β-2 microglobulin (green) and POL polyprotein peptide (pink) (PDB entry 1p7q)

Drag the structure with the mouse to rotate

3D structures of leukocyte immunoglobulin-like receptor

Updated on 10-July-2024

References

  1. ↑ Thomas R, Matthias T, Witte T. Leukocyte immunoglobulin-like receptors as new players in autoimmunity. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):159-62. doi:, 10.1007/s12016-009-8148-8. PMID:19548123 doi:http://dx.doi.org/10.1007/s12016-009-8148-8
  2. ↑ Zeller T, Münnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, Kellner C. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Front Immunol. 2023 Sep 13;14:1240275. PMID:37781391 doi:10.3389/fimmu.2023.1240275
  3. ↑ Mai S, Hodges A, Chen HM, Zhang J, Wang YL, Liu Y, Nakatsu F, Wang X, Fang J, Xu Y, Davidov V, Kang K, Pingali SR, Ganguly S, Suzuki M, Konopleva M, Prinzing B, Zu Y, Gottschalk S, Lu Y, Chen SH, Pan PY. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy. Cancer Res. 2023 Dec 15;83(24):4047-4062. PMID:38098451 doi:10.1158/0008-5472.CAN-22-2483
  4. ↑ Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021 Jul 5;218(7):e20201811. PMID:33974041 doi:10.1084/jem.20201811

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman

Retrieved from "http://52.214.119.220/wiki/index.php/Leukocyte_immunoglobulin-like_receptor"
Personal tools